YUTREPIA™ (treprostinil) inhalation powder
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Liquidia Corporation
Liquidia Corporation is a public biopharmaceutical company that utilizes its proprietary PRINT® (Particle Replication In Non-wetting Templates) technology to design, develop, and commercialize precisely engineered particles for the pharmaceutical industry. Its primary focus is on pulmonary arterial hypertension (PAH), with its lead candidate YUTREPIA™ awaiting final FDA approval and commercial launch. The company's platform enables the creation of inhaled, injectable, and oral products with controlled particle size, shape, and composition, aiming to enhance drug performance and patient outcomes.
View full company profileAbout Liquidia Corporation
Liquidia Corporation is a public biopharmaceutical company that utilizes its proprietary PRINT® (Particle Replication In Non-wetting Templates) technology to design, develop, and commercialize precisely engineered particles for the pharmaceutical industry. Its primary focus is on pulmonary arterial hypertension (PAH), with its lead candidate YUTREPIA™ awaiting final FDA approval and commercial launch. The company's platform enables the creation of inhaled, injectable, and oral products with controlled particle size, shape, and composition, aiming to enhance drug performance and patient outcomes.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| ANPA-0073 | Structure Therapeutics | Preclinical |
| LIQ861 (treprostinil) inhalation powder | Liquidia Corporation | Phase 3 |
| KER-012 | Keros Therapeutics | Phase 2 |
| CS1 | Cereno Scientific | Phase II |
| Seralutinib | Gossamer Bio | Phase 3 |
| NTP42 | ATXA Therapeutics | Phase 1 |